A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year. The Danish pharmaceutical giant said sales of Wegovy ...

The prevalence of obesity in India was lower than in other countries but now it's increasing, Rachel Batterham, senior vice ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...